Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder

Basit Öğe Kaydı
dc.authoridDemirci, Nebi Serkan/0000-0001-5943-889X
dc.authoridSAKIN, Abdullah/0000-0003-2538-8569
dc.authoridSahin, Suleyman/0000-0001-9769-2565
dc.authoridAytekin, Aydin/0000-0002-7001-3945
dc.authorwosidDOGAN, MUTLU/GNP-7311-2022
dc.authorwosidozcelik, melike/AAS-7557-2020
dc.authorwosidDemirci, Nebi Serkan/V-6186-2017
dc.authorwosidbozkaya, yakup/V-6184-2017
dc.authorwosidZengin, Nurullah/KBQ-0049-2024
dc.contributor.authorErdem, Gokmen Umut
dc.contributor.authorDogan, Mutlu
dc.contributor.authorAytekin, Aydin
dc.contributor.authorSahin, Suleyman
dc.contributor.authorCinkir, Havva Yesil
dc.contributor.authorSakin, Abdullah
dc.contributor.authorOzcelik, Melike
dc.date.accessioned2024-06-12T10:54:49Z
dc.date.available2024-06-12T10:54:49Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives There is not yet a standardized approach to treat patients with small cell carcinoma of the bladder (SmCCB). This study aims to investigate the clinical features, treatment, and survival outcomes of patients with pure SmCCB. Materials and methods Patients diagnosed with SmCCB between January 2006 and September 2015 were retrospectively evaluated. Results A total of 34 patients with a median age of 63.0 years were included in the study, with a male to female ratio of 4.6:1.0. At the time of diagnosis, 22 patients (64.7%) had stage IV disease. At a median follow-up time of 12.7 months, 67.6% of patients died of bladder carcinoma, with an overall survival (OS) of 15.7 months for all patients. In the patients with stages I-III, nodal involvement, and distant metastases, the median OS was 31.8, 15.7, and 8.4 months, respectively (P = 0.005). Considering the survival rates of the patients (stages I-III) treated with surgery vs. local therapy, there was not a statistically significant difference (26.6 months and 31.8 months, P = 0.97, respectively). A multivariate analysis revealed that stage IV disease and poor ECOG performance status were associated with OS. Conclusion The optimal treatment of SmCCB has been under debate. For the patients with advanced stage of disease (T4b, N+, M+), platinum containing chemotherapeutic agents should be preferred. Stage IV disease and poor ECOG performance status were associated with shorter OS.en_US
dc.identifier.doi10.1007/s11845-019-02074-9
dc.identifier.endpage438en_US
dc.identifier.issn0021-1265
dc.identifier.issn1863-4362
dc.identifier.issue2en_US
dc.identifier.pmid31463895en_US
dc.identifier.startpage431en_US
dc.identifier.urihttps://doi.org/10.1007/s11845-019-02074-9
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19188
dc.identifier.volume189en_US
dc.identifier.wosWOS:000527933700003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofIrish Journal Of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBladderen_US
dc.subjectChemotherapyen_US
dc.subjectNeuroendocrine Carcinomaen_US
dc.subjectSmall Cell Carcinomaen_US
dc.subjectSurgeryen_US
dc.subjectLong-Term Outcomesen_US
dc.subjectRadical Cystectomyen_US
dc.subjectChemotherapyen_US
dc.subjectCanceren_US
dc.subjectEpidemiologyen_US
dc.subjectSurveillanceen_US
dc.subjectTrendsen_US
dc.titleClinical outcomes of patients with pure small cell carcinoma of the urinary bladderen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu